Scientific deep-dive
Switching Between GLP-1 Drugs
No label contains a dose equivalence between semaglutide and tirzepatide, because no regulator has been asked to approve one. Every conversion chart online is somebody's arithmetic.
People switch between these drugs constantly, whether for supply, cost or side effects, or because one stopped working. The obvious question is what dose you land on, and the answer is that no validated equivalence exists. Every conversion chart circulating online is somebody’s arithmetic, not a labeled fact.
Why there is no conversion
Dose equivalence gets established when a regulator is asked to approve one. Nobody has asked, because no manufacturer has an interest in demonstrating that its drug can be swapped for a competitor’s. So the tables do not exist. The question matters, but no one has been required to answer it.
There is also a mechanistic reason not to expect a clean conversion. Tirzepatide acts at two receptors, GIP and GLP-1; semaglutide acts at one. They are not the same drug at different strengths, and a milligram of one has no defined relationship to a milligram of the other. Our tirzepatide timeline covers why even their trial results cannot be read against each other. At the brand level the labels differ too: Ozempic and Zepbound are approved for different jobs, Ozempic for type 2 diabetes and Zepbound for weight management.
A conversion chart implies a relationship that no regulator has approved and no trial has established.
What the labels actually say
What every label does say is how to start, and they all say it the same way.
- Start at the lowest dose. Every drug in this class has an opening dose intended to be tolerated rather than to work.
- Escalate no faster than every four weeks on the semaglutide and tirzepatide labels. The interval is about the gut adjusting, not about the drug accumulating.
- Increase as tolerated. The labels deliberately leave room for a prescriber to hold or step back.
Applied to a switch, the labels give an unwelcome but consistent default: each drug has its own ladder, and none says where to join it from another drug. Someone comfortable at a high dose of one may still start at the bottom of the other’s ladder, and the weeks that follow can feel like starting over because physiologically they are.
Reasons to switch, ranked by how good they are
- Side effects you cannot tolerate. The best reason, and now supported by comparative data showing that drugs in this class differ measurably by symptom, which we cover in the side-effect ranking. An allergic reaction is a different case: see allergic reactions and anaphylaxis before switching.
- Supply. A real and common reason, and the one that leaves people least choice.
- Cost or coverage. Legitimate, and worth confirming the new price is durable rather than promotional before restarting a ladder. Formularies move too: CVS Caremark dropped Zepbound for Wegovy in 2025 and restored it in October 2026.
- “It stopped working.” The weakest reason on its own, because a plateau is expected rather than a failure, and switching restarts the climb regardless.
What to expect in the gap
These drugs are long-acting, so stopping one does not clear it immediately. Semaglutide has a half-life of about a week, which means meaningful drug remains for several weeks after the last dose. Overlapping two of them is a prescriber’s decision and not a matter of picking a date.
Expect appetite to return before the new drug reaches a working dose. That gap, with the old drug fading and the new one still climbing, is where most of the difficulty of switching lives. Knowing it is coming is most of managing it.
Frequently Asked Questions
References
- 1.GLP Watchdog. FDA-approved labeling for semaglutide and tirzepatide products — titration schedules and the absence of any labeled cross-drug dose equivalence DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/
- 2.Eli Lilly and Company A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2), NCT05706506 ClinicalTrials.gov. 2024. https://clinicaltrials.gov/study/NCT05706506
- 3.Schwartzberg E, Berman E, Shani S, et al. Switching between semaglutide and tirzepatide in obesity Management: an expert-consensus framework for approximate clinical Efficacy-matched switching doses Expert Opinion on Pharmacotherapy. 2026. PMID: 42952336.
Compare the sellers
Related research
A Pill to Hold What the Injection Lost
Daily oral orforglipron maintained 79.3% of weight already lost against 37.6% on placebo at a year in people coming off semaglutide, and 74.7% against 49.2% after tirzepatide. The trial had no arm that stayed on the injection, which is the question people actually have.
5 min read
Many People Never Reach the Dose
Only 58% of people starting semaglutide reached the recommended maintenance dose after four weeks, and 21% stayed on the starting dose. More than half of oral semaglutide starters stopped altogether.
6 min read
Every Other Week: Stretching the Interval
Patients moved to every-other-week dosing after a plateau held their weight and body composition over 36 weeks. It is a case series with no control group, and it is the third of three different ways to use less drug.
5 min read
Why Combination Therapy Fails in Practice
A pragmatic trial of combining two diabetes drugs found 53% filled the prescription against 84% on one drug, and half of those who filled later stopped one. The participants were insured.
5 min read
GLP-1s, Travel and Time Zones
For a weekly injection, time zones barely matter: a week is 168 hours and an eight-hour shift is under 5% of it. The daily oral, anchored to waking rather than the clock, is the one that needs planning.
5 min read
GLP-1 Overdose: What Happens and What to Do
Most GLP-1 overdoses are dosing mistakes with compounded vials and cause severe nausea and vomiting that can last days. The guidance on the Ozempic, Wegovy, Mounjaro and Zepbound labels, FDA's dosing-error alert, and when to call Poison Help or 911.
10 min read
Where to get tirzepatide online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Collective
From $69/mo + membership
Get started →Embody
From $129/mo
Get started →Bodybuilding Health+
Seeing what it charges before you answer any medical questions
From $209/mo
Get started →